Skip to main content

Pairings: Mar 4, 2009

Premium

Navigenics announced last week that Mari Baker, president and CEO of the company since its inception in 2007, would step down from her post to pursue other opportunities.

The company's board of directors "is actively interviewing candidates for the president and CEO position," Navigenics said in a statement. In the meantime, board members Dana Mead and Sue Siegel will work together with the existing executive team to lead the company.

Baker's departure occurred this week. She will continue to serve as a board.


Illumina CEO Jay Flatley has joined the board of directors of Helixis, a developer of nucleic acid analysis tools. Prior to joining Illumina, Flatley was president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that company's initial public offering in 1993.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.